๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Hormonal Therapy for Advanced Prostatic Carcinoma

โœ Scribed by Allen D. Seftel; J. Patrick Spirnak; Martin I. Resnick

Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
841 KB
Volume
42
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

โœฆ Synopsis

Since the work of Huggins and Hodges, hormonal therapy, i.e., orchiectomy or estrogens, has been the gold standard of treatment for patients with advanced adenocarcinoma of the prostate. Recently, many new drugs have been introduced in the hope of achieving a beneficial response as compared with hormonal therapy, while avoiding some of the adverse effects. Various newer agents are reviewed. It appears that while these agents may be attractive secondary to specific effects, they do not appear to offer any survival advantage over diethylstilbestrol or orchiectomy .

Finally, the theory of total androgen blockade is reviewed. Institution of total blockade does not appear to offer a survival advantage over standard androgen blockade.

๐Ÿ“œ SIMILAR VOLUMES

Early results of a prospective study of
Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma
โœ Jackson E. Fowler Jr.; Steven A. Bigler; John M. Kolski; David T. Yee ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 85 KB ๐Ÿ‘ 3 views

## Background: Locally advanced prostate carcinoma is usually not curable with surgery or radiation therapy. primary hormone therapy is an alternative therapeutic option, but contemporary prospective studies of the outcomes of such therapy are not available. ## Methods: The authors conducted a pr

Hormone therapy adjuvant to external bea
Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma : A complication-adjusted number-needed-to-treat analysis
โœ Ashesh B. Jani; Johnny Kao; Samuel Hellman ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 125 KB

## Background: Hormone therapy commonly is used to treat metastatic, locally advanced, and localized prostate carcinoma. the objective of the current investigation was to determine, using the number-needed-to-treat (nnt) method, the effect of using hormone therapy to treat locally advanced disease,

Combined hormonal therapy with high-dose
Combined hormonal therapy with high-dose diethylstilbestrol diphosphate (DES-DP) intravenous infusion plus vindesine (VND) for the treatment of advanced prostatic carcinoma: A controlled study
โœ Juan C. Cervellino; Carlos E. Araujo; Claudia Pirisi; Oscar Podskubka; Eduardo M ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 335 KB

Fifty-one patients with stage D prostate cancer, who had failed primary hormone treatment, were treated with diethylstilbestrol diphosphate (DES-DP) 1.5 g 24 hr intravenous infusion from day 1 to day 7 (group A). In group B, patients were treated with DES-DP as in A, plus vindesine (VND) 3 mg/m2 int